WFS1 and amyotrophic lateral sclerosis: A combination of 4-phenylbutyrate and tauroursodeoxycholic acid, also recently approved in the United States for the treatment of ALS [21], increased WFS1 levels, alleviated ER stress and inhibited cellular apoptosis in patient-derived induced pluripotent stem cells.